In a patient with grade 2 triple‑positive (ER‑positive, PR‑positive, HER2‑positive) breast cancer that has not yet been staged, should a PET scan be recommended for staging?

PET Scan Recommendation for Grade 2 Triple-Positive Unstaged Breast Cancer

PET/CT should NOT be routinely recommended for your patient until clinical staging is completed with standard locoregional imaging (mammography, breast/axilla ultrasound ± breast MRI), and then only if the clinical stage is IIB or higher. 1

Staging Algorithm

The decision to use PET/CT depends entirely on the clinical stage determined by physical examination and locoregional imaging:

Stage I (T1N0): Do NOT use PET/CT

• PET/CT is explicitly not recommended 1
• Risk of distant metastases is extremely low
• False positive rate (3.0%) exceeds true positive rate (0.9%) 1
• PET has limited spatial resolution (~5-6mm) and performs worse than sentinel node biopsy 1

Stage IIA (T1N1 or T2N0): May consider but not routinely recommended

• Evidence is mixed with upstaging rates of 0.8-11% 1
• Triple-positive tumors show 4% distant metastases detection in stage IIA 2
• Clinical judgment call: Consider if T2 tumor >3cm or node-positive 1

Stage IIB or higher: PET/CT IS recommended

• Strong recommendation for baseline staging 1
• Detects unsuspected distant metastases in 14% of stage IIB patients with triple-positive disease 2
• Stage III shows 22-26% upstaging across all subtypes 2
• Use PET/CT INSTEAD OF (not in addition to) conventional staging (bone scan + chest CT + abdominal imaging) 1

Stage III (including inflammatory): PET/CT strongly recommended

• Upstaging occurs in 22-26% of cases 2
• Critical for treatment planning and radiation therapy planning 1

Key Considerations for Triple-Positive Disease

Your patient's triple-positive (ER+/PR+/HER2+) biology is relevant:

• HER2-positive tumors have more extra-skeletal metastases than hormone receptor-positive/HER2-negative tumors 1
• Triple-positive disease shows similar upstaging rates (14% in stage IIB) to triple-negative disease 2
• Recent data (2025) suggests high-risk subtypes (including HER2+) benefit more from PET/CT, though this study grouped HER2+ with triple-negative 3

Common Pitfalls to Avoid

1. Do NOT order PET/CT before completing clinical staging with standard breast imaging—the guidelines are stage-dependent 1

2. Avoid "overuse" in early-stage disease: Despite 85% of stage I-II patients receiving PET/CT in some centers, only 4.9% are upstaged, representing guideline-discordant care 4

3. Do NOT combine PET/CT with conventional staging (bone scan, CT chest/abdomen)—use one or the other to avoid redundancy and false positives 1

4. Grade 2 histology alone does not determine PET/CT indication—clinical stage and nodal status are the primary drivers 1

Practical Next Steps

1. Complete clinical staging first: Physical exam + mammography + breast/axilla ultrasound ± MRI
2. Determine clinical T and N stage using AJCC 8th edition criteria
3. Apply algorithm above based on resulting clinical stage
4. If stage IIB or III: Order PET/CT for baseline staging before definitive treatment
5. If stage I or IIA: Proceed with standard surgical staging (sentinel node biopsy)

The 2024 EANM-SNMMI joint guideline provides the most current, consensus-based framework and should guide your decision 1.